By Elias Schisgall
Nvidia and Eli Lilly are partnering to launch a co-innovation lab to use Nvidia's artificial-intelligence and robotics expertise for drug discovery.
The companies said Monday they would invest up to $1 billion in talent, infrastructure, and computing power, including Nvidia's Vera Rubin chips, over the next five years. They said the new lab would expand the buildout of Lilly's Nvidia DGX SUperPOD and AI factory.
Lilly Chief Information and Digital Officer Diogo Rau said the partnership reflected the growing centrality of artificial-intelligence technology in drug discovery.
"We're moving toward a future where discovery is driven by rapid experimentation and increasingly customized models -- an approach that reflects our commitment to leading applied AI in drug discovery and investing deeply in new forms of data generation and model development," Rau said Monday.
The companies had previously teamed up in October to announce the construction of a new supercomputer focused on drug discovery, built using more than 1,000 of Nvidia's Blackwell chips.
Nvidia said Monday that it was also collaborating with Thermo Fisher to help automate the company's research laboratory equipment.
The company also said it was expanding its BioNeMo platform, an open-development AI training and modeling platform focused on the life sciences industry. It said it had incorporated new models into the platform, including models for synthesizing AI-designed drugs and predicting RNA structures.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
01-12-26 1041ET
